Crizotinib demonstrated superior efficacy over chemotherapy in ALK-rearranged NSCLC patients, and ceritinib was also highly active in patients who had disease progression after crizotinib treatment [7–9]. This evidence concerns the gene ALK and non-small cell lung carcinoma.